Click here to view online. Add this email to your safelist.
Tezepelumab is the first biologic to consistently and significantly reduce exacerbations in broad population of severe asthma patients
26 February 2021
Positive full results from the pivotal NAVIGATOR Phase III trial showed AstraZeneca and Amgen’s tezepelumab demonstrated a statistically significant and clinically meaningful reduction in the annualised asthma exacerbation rate (AAER) in severe, uncontrolled asthma patients. The results were presented at the American Academy of Asthma Allergy & Immunology Virtual Annual Meeting.
|
|||||
|
|||||
|
For more information please visit astrazeneca.com. If you would like to unsubscribe please click here. |
